(Q85112549)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20882023%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

title

Therapy: Immunogenicity of biologic therapies-we need tolerance (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20882023%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

author name string

Charlotte L M Krieckaert

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20882023%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

G Margret Bartelds

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20882023%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

Gerrit-Jan Wolbink

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20882023%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

publication date

1 October 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20882023%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Rheumatology

14 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20882023%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20882023%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20882023%20AND%20SRC:MED&resulttype=core&format=json

14 February 2020

page(s)

558-559

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:20882023%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrrheum.2010.153

14 February 2020

exact match

0 references

cites work

Dealing with immunogenicity of biologicals: assessment and clinical relevance

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.153

Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.153

Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.153

A Novel Strategy To Reduce the Immunogenicity of Biological Therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.153

CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.153

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.153

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.153

Infliximab, azathioprine, or combination therapy for Crohn's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.153

Optimization algorithms for functional deimmunization of therapeutic proteins

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2010.153

Elimination of the immunogenicity of therapeutic antibodies

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20882023